Long-Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response With Risankizumab in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
September 2023
in “
Journal of the American Academy of Dermatology
”
Studysummary Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer